FN-1501
- Generic Name
- FN-1501
- Brand Names
- Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N9O
- CAS Number
- 1429515-59-2
- Unique Ingredient Identifier
- 6MC966B505
- Background
Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...
- Indication
Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...
- Associated Conditions
- Transplanted Organ Rejection
- Associated Therapies
- -
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 63
- Registration Number
- NCT03032783
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Registry of IgA Nephropathy in Chinese Children
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 1200
- Registration Number
- NCT03015974
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases
- Conditions
- Interventions
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- University Hospital, Tours
- Target Recruit Count
- 122
- Registration Number
- NCT02990286
- Locations
- 🇫🇷
AP-HM Hôpital NORD, Marseille, France
🇫🇷Chu Rennes, Rennes, France
🇫🇷Chu Besancon, Besancon, France
Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 100
- Registration Number
- NCT02981212
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT02981290
- Locations
- 🇳🇿
Christchurch Clinical Studies Trust, Christchurch, New Zealand
Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 25
- Registration Number
- NCT02953873
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 40
- Registration Number
- NCT02954198
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Genovate Biotechnology Co., Ltd.,
- Target Recruit Count
- 32
- Registration Number
- NCT02949349
De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study
- Conditions
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Rennes University Hospital
- Registration Number
- NCT02909335
Alipogene Tiparvovec for the Treatment of LPLD Patients
- Conditions
- Interventions
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- UniQure Biopharma B.V.
- Registration Number
- NCT02904772
- Locations
- 🇺🇸
Perelman School of Medicine at The University of Pennsylvania Translational Medicine & Human Genetics, Philadelphia, Pennsylvania, United States
🇨🇦Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.